BRAIN |
A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND# 60, 265) versus Radiation Therapy and BCNU for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant) |
ECOG |
R98-13 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
BREAST (Adjuvant) |
Cyclophosphamide and Doxorubicin (CA) (4 vs 6 cycles) Versus Paclitaxel (12 weeks vs 18 weeks) as Adjuvant Therapy for Women with Node-Negative Breast Cancer A 2x2 Factorial Phase III Randomized Study |
CALGB |
40101 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil or Doxorubicin and Cyclophosphamide vs. Capecitabine in Women 65 yrs & Older with Node Positive or High-Risk Node Negative Breast Cancer |
CALGB |
49907 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Clinical Trial Comparing Anastrozole or Tamoxifen in Postmenopausal Patients with Ductal Carcinoma in SITU (DCIS) Undergoing Lumpectomy with Radiation Therapy |
NSABP |
B-35 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
| A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC -> P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -> PG) |
NSABP |
B-38 |
Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
| Phase II Study of Doxil and Carboplatin, plus Herceptin in HER2+Patients, in Metastatic Breast Cancer (MBC) |
USON |
004111 |
Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer |
SWOG |
0221 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
BREAST (Metastatic) |
An Open-label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combination with Intravenous Docetaxel (Q3W) In Patients with Locally Advanced and/or Metastatic Breast Cancer |
Roche |
NO16853B |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) with or without Cetuximab (Erbitux) in Patients with Metastatic Breast Cancer |
USON |
04070 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
GASTROINTESTINAL (Colon/Rectal) |
PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With Metastatic Colorectal Cancer |
AMGEN |
20040249 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer |
CTSU/NCCTG |
N0147 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin, and Bevacizumabin Pts. With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers |
ECOG |
5202 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer |
ECOG |
4203 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial |
ECOG |
E4298 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
"XELOX-A-DVS" (Dense Vs Standard): A Randomized Study of Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q3W) and Bevacizumab versus Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (ML18491) |
USON |
05003 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
GASTROINTESTINAL (Gastric) |
| A Phase III Trial of Adjuvant Chemoradiation after Resection of Gastric and Gastroesophageal Adenocarcinoma |
CALGB |
80101 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma |
ECOG |
5203 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
GASTROINTESTINAL (Hepatic) |
| A Phase II Trial of Bortezomib Plus Doxorubicin in Hepatocellular Carcinoma |
ECOG |
6202 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax). Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial |
ECOG |
4298 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax)
|
GASTROINTESTINAL (Pancreatic) |
| A Randomized, Open-Label Phase 2 Studyt of 2 Regimens, Gemcitabine plus Enzastaurin and Single-Agent Gemcitabine, in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
USON |
05044 |
Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Phase 2 Trial of Irinotecan/Docetaxel for Adv. Pancreatic Cancer, with Randomization between Irinotecan/Docetaxel & Irinotecan/Docetaxel Plus C225 a Monoclonal Antibody to the Epidermal Growth Factor Receptor. This study is suspended to accrual |
ECOG |
8200 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
GASTROINTESTINAL (Rectal) |
| Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation |
ECOG |
5204 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Clinical Trial Comparing Preop Radiation and Xeloda with/without Oxaliplatin with preop radiation and continuous IV of 5 FU with/without Oxaliplatin in the tx of pts. With operable carcinoma of the rectum |
NSABP |
R-04 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
ENDOMETRIAL |
No Current Trials |
|
|
|
ESOPHAGEAL |
No Current Trials |
|
|
|
GENITOURINARY (Bladder) |
A Phase II Random. Trial for Pts. With Ms. Invading Bladder Ca. Evanluat. Transurethral Surgery and BID Irradiation Plus either Paclitaxel and Cisplatin or 5-FU and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cispl.Adj |
RTOG |
0223 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
GENITOURINARY (Prostate) |
Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III |
ECOG |
S9346 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Phase II Study of PROSTV AC-V (Vaccinia)/TRICOM and PROSTV AC-F (Fowlpox)/TRICOM with GM-CSF in Patients with PSA Progression After Local Therapy for Prostate Cancer |
ECOG |
9802 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
GENITOURINARY (Renal) |
| A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitnib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carincoma |
ECOG |
2805 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features |
ECOG |
8802 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Phase II Trial of Paclitaxel Plus Carboplatin in Patients with Metastatic or Locally Advanced Collecting Duct Renal Cell Cancer |
ECOG |
2803 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
HEAD & NECK (Advanced) |
Phase II of PS-341 (NSC 681239) Followed by the Addition of Doxorubicin at Progression in Advanced Adenoid Cystic Carcinoma of the Head and Neck SUSPENDED |
ECOG |
1303 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer |
ECOG |
1302 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
LEUKEMIA (ALL) |
Phase III Randomized Trial of Autologous and Allogeneic Bone Marrow Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission. |
ECOG |
2993 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
LEUKEMIA (AML) |
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure |
ECOG |
2902 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification and Gemtuzumab-Ozogamicin Consolidation Therapy prior to Autologous Stem Cell Transplantation |
ECOG |
1900 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
LEUKEMIA (CLL) |
Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed By Campath-1H For Previously Treated Relapsed or Refractory Patients With Chronic Lymphocytic Lymphoma |
ECOG |
2903 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
LEUKEMIA (CML) |
A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase |
ECOG |
S0325 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
LEUKEMIA (Laboratory) |
Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders |
ECOG |
3903 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
LEUKEMIA (Miscellaneous) |
A Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia |
ECOG |
5998 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A prospective, randomized, open label, phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in previously untreated or treated b-cell chronic lymphocytic leukemia |
USON |
03017 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
LUNG (Non Small Cell) |
A Randomized Multicenter Phase II Study of Taxane/Carbo/Cetuximab versus Taxane/Carbo as First-Line treatment for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer |
BMS |
CA22599 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
| A Randomized, Open-Label Phase II Study of Pemetrexed (Alimta) plus Carboplatin with or without Enzastaurin Hydrochloride, or Docetaxel plus Carboplatin as First Line Treatment in Patients with Advanced Stage Non-Small Cell Lung Cancer (NSCLC) |
USON |
05082 |
Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy With or Without Thalidomide, in Patients with Stage III NSCLC |
ECOG |
3598 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Double Blind Phase II Study of BAY-43-9006 in Patients with Non-Small Cell Lung Cancer who have Failed at Least Two Prior Chemotherapy Regimens |
ECOG |
2501 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus (Pancoast Tumors) |
ECOG |
S0220 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
BETA: Phase III / Double-Blind / Placebo-Controlled Trial of Bevacizumab in Combination with Tarceva Compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer After Failure of Standard First Line Chemo |
Genentech
/OSI |
OSI3364g |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Molecular Profiling of Non-Small cell Lung Cancer with Clinical Correlations |
Rush |
LUNG TISSUE |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in chemonaive patients with Stage IIIB-IV non-small cell lung cancer |
BAYER |
11961 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
LUNG (NSCLC) |
Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer |
ECOG |
5597 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Randomized Trial of Carboplatin/Gemcitabine vs. Gemcitabine alone in PS2 Patients with Advanced (Stage IIIB or IV) NSCLC |
USON |
03012 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
LUNG (Laboratory) |
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men |
SWOG |
0424 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
LUNG (Thymoma) |
Phase II Study of Carboplatin plus Paclitaxel Treatment of Advanced Thymoma or Thymic Carcinoma |
ECOG |
1C99 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
LYMPHOMA (Hodgkins) |
|
|
|
|
LYMPHOMA (Non Hodgkins) |
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell LymphomaA Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma |
ECOG |
2402 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Randomized Phase III Trial of Rituximab (NSC #687451) and Autologous Stem Cell Transplantation for B Cell Diffuse Large Call Lymphoma |
ECOG |
2499 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
Early High Dose Chemoradiotherapy and ASCT to Conventional Dose CHOP Chemotherapy (with possible Late ASCT) for Patients with Diffuse, Aggressive NHL |
ECOG |
S9704 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Low Tumor Burden Patients with Indolent Non-Hodgkin's Lymphoma |
ECOG |
4402 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Phase II Trial of R-CHOP Followed By Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma |
ECOG |
3402 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
A Randomized Phase II Trial of Outpatient Immunotherapy with Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for CD20 Positive Aggressive Non-Hodgkin's Lymphoma Following High Dose Therapy with Autologous PBSC Rescue |
USON |
04099 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
MELANOMA (High Risk) |
Randomized Study of Four Weeks High Dose Interferon Alpha-2b in Stage IIa Melanoma |
ECOG |
E1697 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
Yeast Derived GM-CSF Versus Peptide Vaccination Vs. GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma |
ECOG |
4697 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma |
ECOG |
S0008 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
MELANOMA (Metastatic) |
Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor |
ECOG |
2602 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax).Ira A. Oliff, M.D., Susan Brown, M.D., Teresa Law, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
A Randomized Phase II Trial of Multi-epitope Vaccination with Melanoma Peptides for Cytotoxic T cells and Helper T cells for Patients with Metastatic Melanoma |
ECOG |
1602 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
MESOTHELIOMA |
No Current Trials |
|
|
|
MULTIPLE MYELOMA |
A Phase II Open-label Trial of Velcade in Velcade-naive Patients with Multiple Myeloma who have undergone High-dose Melphalan Therapy followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response |
USON |
03047 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
MYELODYPLASTIC SYNDROME |
No Current Trials |
|
|
|
OVARIAN |
Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by elective Paclitaxel Consolidation versus Paclitaxel and Carboplatin Followed by elective Paclitaxel Consolidation in Patients with Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian tube Carcinoma (D) (B9E-US-S302) |
USON |
02044 |
Ira A. Oliff, M.D.
9711 Skokie Blvd,
Ste A
Skokie, IL 60076
847-568-9930 |
SARCOMA |
A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary GastroIntestinal Stromal Tumor (GIST) (ECOG endorsed / CTSU) |
ACOSOG |
Z9001 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
|
|
|
|
TESTICULAR |
No Current Trials |
|
|
|
MISCELLANEOUS |
ECOG Laboratory Study: Mapping Interactive Cancer Susceptibility Loci |
ECOG |
E1Y97 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |
MISCELLANEOUS (Anemia) |
|
|
|
|
MISCELLANEOUS (Catheter Occlusion) |
SONOMA 2: Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Occluded Central Venous Access Devices |
Nuvelo |
HA006 |
Edward Kaplan, M.D., Marlon Kleinman, M.D.
9631 Gross Point Rd.
Suite 10
Skokie, IL 60076
847.675.3900 (phone)
847.675.3930 (fax) |